- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mo | Transcode Therapeutics, Inc. - 8-K, Current Report | 12 | SEC Filings | ||
| 15.04. | Transcode Therapeutics, Inc. - 10-K, Annual Report | 5 | SEC Filings | ||
| 31.03. | Transcode Therapeutics, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 5 | SEC Filings | ||
| 27.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 | 137 | PR Newswire | First patient in Cohort four has been treated with TTX-MC138
Ten patients have been treated with TTX-MC138 at escalating dose levels
Additional patients being... ► Artikel lesen | |
| 25.03. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.03. | TransCode Therapeutics Announces $10M Stock And Warrant Offering | 1 | RTTNews | ||
| 24.03. | TransCode Therapeutics stock slides after announces to raise $10M securities offering | 5 | Seeking Alpha | ||
| 21.03. | TransCode Therapeutics Stock Surges 85% | 15 | RTTNews | ||
| 21.03. | Pre-market Movers: Allurion Technologies, Impact BioMedical, Patriot National Bancorp, TransCode Therapeutics, DSS, Inc. | 564 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 64% at... ► Artikel lesen | |
| 13.03. | TransCode Therapeutics Advances Phase I Trial Of RNA Cancer Therapy | 5 | RTTNews | ||
| 13.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial | 183 | PR Newswire | Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3
No significant... ► Artikel lesen | |
| 25.02. | TransCode Therapeutics, Inc. Announces Results of Special Meeting | 555 | PR Newswire | BOSTON, Feb. 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more... ► Artikel lesen | |
| 25.02. | Transcode Therapeutics, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 06.02. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial | 260 | PR Newswire | No significant safety or dose limiting toxicities reported
PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results
BOSTON, Feb.... ► Artikel lesen | |
| 24.01. | TransCode Therapeutics Shares Are Surging Today: What's Going On? | 15 | Benzinga.com | ||
| 07.01. | TransCode Therapeutics regains compliance with Nasdaq | 5 | Seeking Alpha | ||
| 20.12.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.12.24 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial | 206 | PR Newswire | Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2
No significant safety or dose limiting toxicities... ► Artikel lesen | |
| 06.12.24 | Transcode Therapeutics, Inc. - S-1, General form for registration of securities | 11 | SEC Filings | ||
| 02.12.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 104,80 | +2,54 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
| QIAGEN | 37,450 | -0,43 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
| NOVAVAX | 6,261 | +1,03 % | Novavax Aktie: Optimistische Umsatzprognosen! | Die Novavax-Aktie gewinnt über 20% nach positiven Signalen der FDA zur COVID-19-Impfstoffzulassung. Weitere Studien sind jedoch erforderlich. Die Novavax-Aktie zeigt heute eine beeindruckende Rallye... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,188 | +3,18 % | Palatin Aktie: Gefährdete Stabilität! | Biotech-Firma Palatin kämpft gegen Börsenausschluss, während Orphan-Drug-Kandidat Hoffnung weckt. Kann die Pipeline die Finanzkrise abwenden? Die Uhr tickt für Palatin Technologies: Das Biotech-Unternehmen... ► Artikel lesen | |
| BRAIN BIOTECH | 2,370 | +1,28 % | EQS-News: BRAIN Biotech AG: Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Hauptversammlung
Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG
18.03.2025 / 16:45 CET/CEST
Für... ► Artikel lesen | |
| VIVOSIM LABS | 1,930 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,680 | -0,59 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,580 | +1,57 % | COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer | 25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO... ► Artikel lesen | |
| GENMAB | 179,15 | -0,61 % | H.C. Wainwright maintains Buy on Genmab shares, $37 price target | ||
| XOMA ROYALTY | 20,800 | -1,89 % | Spotlight Stock Market: Market Notice 68/25 - Information regarding the rights issue from Xoma AB | ||
| T2 BIOSYSTEMS | 0,118 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,220 | 0,00 % | Phio Pharmaceuticals Corp. - 8-K, Current Report | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-K, Annual Report | ||
| ORAGENICS | 0,194 | 0,00 % | Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress | SARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today... ► Artikel lesen | |
| LADRX | - | - | LadRx Corp - 8-K, Current Report |
TRANSCODE THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,394 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.
